<DOC>
	<DOCNO>NCT00728195</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety 3 fixed dos JNJ-37822681 compare placebo ( inactive substance compare drug test drug real effect clinical trial ) 6 week treatment olanzapine 12 week treatment participant schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusion hallucination , withdrawal self ) .</brief_summary>
	<brief_title>An Efficacy Safety Study 3 Fixed Doses JNJ-37822681 Participants With Schizophrenia</brief_title>
	<detailed_description>This multicenter ( one hospital medical school team work medical research study ) , double-blind ( neither participant physician know study medication drug name ) , randomize ( study drug assign chance ) , placebo- active-controlled , parallel-group ( clinical trial compare response two group participant receive different treatment ) , dose-response study participant schizophrenia . The total study duration exceed 16 week participant include follow visit : screening , baseline , Week 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 11 13 ( end treatment early withdrawal ) , post-study safety visit ( 1 week final dose study drug ) . All participant hospitalize first 2 week treatment detail follow-up safety disease status . Following screening period , participant randomly assign one 5 treatment group receive oral dos JNJ-37822681 ( 10 , 20 30 milligram [ mg ] twice day ) 12 week , olanzapine 15 mg daily 12 week , placebo 6 week follow olanzapine 15 mg daily remain 6 week . Olanzapine initiate 10 mg daily 1 week increase 15 mg daily remainder treatment period . Efficacy primarily evaluate Positive And Negative Syndrome Scale ( PANSS ) . Participants ' safety also monitor visit .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>N- ( 1- ( 3,4-difluorobenzyl ) piperidin-4-yl ) -6- ( trifluoromethyl ) pyridazin-3-amine</mesh_term>
	<criteria>Participants must diagnose schizophrenia accord Diagnostic Statistical Manual Mental Disorders , 4th edition ( DSMIV ) ( 295.10 , 295.20 , 295.30 , 295.60 , 295.90 ) least 1 year prior screen Participants must experience acute ( quick severe form illness early stage ) exacerbation le 6 month duration , Positive Negative Syndrome Scale ( PANSS ) total score screen 70 120 inclusive baseline 60 120 inclusive Women child bear potential must negative urine pregnancy test screen baseline receive study drug Participants must agree voluntary hospitalization minimum 14 day BMI ( Body Mass Index ) maximum 40 kilogram per meter square ( kg/m^2 ) , inclusive ( BMI=weight/height^2 ) A DSMIV axis I diagnosis schizophrenia A DSMIV diagnosis substance dependence within 6 month prior screen evaluation Any clinically relevant medical condition could potentially alter absorption ( way drug substance enters body ) , metabolism , excretion ( way substance leave body ) study medication , Crohn 's disease ( serious inflammation part gastrointestinal tract ) , liver disease , renal ( pertain kidney ) disease Relevant history significant and/or unstable cardiovascular ( pertain heart blood vessel ) , respiratory , neurological ( include seizure ) significant cerebrovascular ( pertain brain blood vessel ) , renal , hepatic , endocrine ( pertain gland make hormone ) , immunologic disease History neuroleptic malignant syndrome ( high fever , rigid muscle , shake , confusion , sweat usual , increased heart rate blood pressure , muscle pain weakness )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Central Nervous System</keyword>
	<keyword>JNJ-37822681</keyword>
</DOC>